Drug intelligence / Profile preview

AVT002

Development stage: Preclinical
Lead developer: Avotres
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AVT002 is a monoclonal antibody being developed by Avotres Inc. as a potential cancer therapy directed at a novel, undisclosed immuno-oncology target. Currently in the preclinical stage, the drug is intended to reduce both early and late-stage cancer recurrence and may serve as a synergistic combination therapy with checkpoint inhibitors. Preclinical evidence includes demonstrated efficacy in a mouse melanoma model, supporting its development for immuno-oncology indications and the prevention of cancer recurrence.

Beyond the preview

Go deeper on AVT002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVT002.

Explore the full profile